Acomplia SERENADE Data Is Music To Sanofi’s Ears
This article was originally published in The Pink Sheet Daily
Executive Summary
Results of the study of rimonabant in type 2 diabetes patients shows improvements in blood sugar, weight and other risk factors.
You may also be interested in...
Sanofi Withdraws Zimulti NDA For Weight Loss
Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.
Sanofi Withdraws Zimulti NDA For Weight Loss
Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.
Acomplia User Fee Date For Weight Loss Is April 26
Sanofi-Aventis has not determined a timetable for responding to FDA’s “not approvable” letter for a smoking cessation claim.